The BMP2 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the 769-P clear cell renal carcinoma line, featuring targeted disruption of the BMP2 gene. This loss-of-function model eliminates endogenous BMP2 ligand production across the cell pool, enabling functional studies without monoclonal selection. The knockout cells serve as a valuable tool for investigating BMP2-dependent pathways in an epithelial cancer background.
The 769-P cell line originates from a primary clear cell renal cell carcinoma and exhibits adherent epithelial morphology. It is a widely used model for ccRCC, retaining key oncogenic pathways and providing a clinically relevant context for probing BMP signaling in renal tumorigenesis.
BMP2 is a TGF-?? superfamily secreted ligand that activates signaling through heteromeric complexes of type I (BMPR1A/B) and type II (BMPR2) receptors, leading to phosphorylation of SMAD1/5/8. These phospho-SMADs associate with SMAD4 and induce expression of target genes such as ID1, ID2, ID3, RUNX2, and SP7. Extracellular inhibitors like Noggin, Chordin, and Gremlin modulate BMP2 availability, while co-receptors including Endoglin and Betaglycan fine-tune receptor binding. BMP2 also engages non-canonical MAPK/ERK and PI3K/Akt pathways, integrating signals that govern proliferation, differentiation, and apoptosis. Upstream regulators such as HIF1A, TNF-??, and IL-1?? further influence BMP2 expression.
In 769-P cells, BMP2 ablation is expected to abolish SMAD1/5/8 phosphorylation, reduce ID gene expression, and disrupt MAPK/ERK and PI3K/Akt crosstalk, thereby altering cell proliferation, migration, and EMT. The loss of BMP2 is anticipated to impair SMAD-mediated transcription and alter non-canonical signaling via MAPK/ERK and PI3K/Akt, providing a clean background to evaluate pathway-specific contributions to tumor cell behavior. This model is particularly relevant for studying ccRCC progression and bone metastasis, as BMP2 is implicated in osteogenic signaling and metastatic colonization of bone.
Researchers can employ these polyclonal knockout cells to dissect BMP2 function in renal carcinoma, analyze EMT dynamics, screen BMP pathway modulators, or perform osteogenic differentiation assays. Compatible techniques include western blotting for phospho-SMAD1/5/8, RT-qPCR of ID1 and RUNX2, RNA-seq, immunofluorescence, proliferation and migration assays, and reporter gene studies. Additionally, co-immunoprecipitation experiments can assess receptor interactions, and apoptosis assays gauge cell death responses following pathway disruption. For ordering or technical inquiries, please reach out to Ascent Research.
